Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus
Main finding · Prevalence of MAFLD with coexisting significant fibrosisResult — go to the resultUnadjusted odds ratio 0.32 95% CI 0.14–0.70Authors' conclusion
The lower prevalence of MAFLD with coexisting significant fibrosis we observed in adults with T1DM using CSII therapy, compared to those using MDI therapy, is primarily mediated by inter-group differences in age.
Study context
- Population
- Adults with established T1D treated with multiple daily injections (MDI) or CSII; MAFLD defined by hepatic steatosis index (HSI) >36, significant fibrosis by FIB-4 index ≥ 1.3multicenter
- Participants
- 1,417 adults
- Exposure
- CSII vs MDI
- CSIIn = 256
- MDIn = 1,161reference
- Outcome
- MAFLD with or without coexisting significant liver fibrosis (non-invasive biomarkers)
Methodological detailsmulticenter
- Multicenter
Main finding
As reported in the abstract
Prevalence of MAFLD with coexisting significant fibrosis
Unadjusted odds ratio
0.32
95% CI 0.14–0.70
P = 0.004
By group
CSIIvs MDI
unadjusted OR 0.32 (95% CI 0.14–0.70); P = 0.004
Observational data: associations, not effects.
Further findings
Age
P < 0.001
HbA1c
P = 0.025
Original publication
Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus. Diabetes Metab. Published 12 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →